# EDGAR Filing Document

**Accession Number:** 0000895464
**File Stem:** 0001640334-25-000982
**Filing Date:** 2025-6
**Character Count:** 8975
**Document Hash:** e009e55414fad7baf3cf489b538b8813
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640334-25-000982.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001640334-25-000982

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20240125

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Boao Biotech Ltd
- **CENTRAL INDEX KEY:** 0001841399

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-21320
- **FILM NUMBER:** 251019007

**BUSINESS ADDRESS:**
- **STREET 1:** C/O YUBO INTERNATIONAL BIOTECH LIMITED
- **STREET 2:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** XICHENG DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86 010 6615 5141

**MAIL ADDRESS:**
- **STREET 1:** C/O YUBO INTERNATIONAL BIOTECH LIMITED
- **STREET 2:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** XICHENG DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 00000
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** CAO YULIN
- **CENTRAL INDEX KEY:** 0002067350

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-21320
- **FILM NUMBER:** 251019006

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** WICKHAM'S CAY II, TORTOLA
- **STREET 2:** C/O BOAO BIOTECH LIMITED; POBOX 2221
- **CITY:** ROAD TOWN
- **PROVINCE COUNTRY:** D8
- **ZIP:** VG1110
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Yubo International Biotech Ltd
- **CENTRAL INDEX KEY:** 0000895464
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 113074326
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86 (010) 6615-5141

**MAIL ADDRESS:**
- **STREET 1:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MAGNA LAB INC
- **DATE OF NAME CHANGE:** 19940722

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Boao Biotech Ltd<br><sub>(Last) (First) (Middle)</sub><br>C/O WICKHAMS CAY II<br>P.O. BOX 2221, ROAD TOWN<br><sub>(Street)</sub><br>TORTOLA, D8 00000<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2024-01-25-05:00 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Yubo International Biotech Ltd [ YBGJ ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>CAO YULIN<br><sub>(Last) (First) (Middle)</sub><br>C/O WICKHAMS CAY II<br>P.O. BOX 2221, ROAD TOWN<br><sub>(Street)</sub><br>TORTOLA, D8 00000<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2024-01-25-05:00 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Yubo International Biotech Ltd [ YBGJ ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Stock | 2024-01-25-05:00 |  | S |  | 500000 | D | $0.30 | 24467800 | D |  |
| Class A Common Stock | 2024-01-25-05:00 |  | S |  | 741521 | D | $0.30 | 23726279 | D |  |
| Class A Common Stock | 2024-01-25-05:00 |  | S |  | 301701 | D | $0.30 | 23424578 | D |  |
| Class A Common Stock | 2024-01-25-05:00 |  | S |  | 364351 | D | $0.30 | 23060227 | D |  |
| Class A Common Stock | 2024-01-25-05:00 |  | S |  | 181256 | D | $0.30 | 22878971 | D |  |
| Class A Common Stock | 2024-01-25-05:00 |  | S |  | 86897 | D | $0.30 | 22792074 | D |  |
| Class A Common Stock | 2024-01-25-05:00 |  | S |  | 426654 | D | $0.30 | 22365420 | D |  |
| Class A Common Stock | 2024-01-25-05:00 |  | S |  | 2057586 | D | $0.30 | 20307834 | D |  |
| Class A Common Stock | 2024-01-25-05:00 |  | S |  | 380174 | D | $0.30 | 19927660 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

**Remarks:**
The shares of Class A Common Stock of the Issuer are held directly by Boao Biotech Ltd. Mr. Yulin Cao is the sole Director of Boao Biotech Ltd, and as such, Mr. Yulin Cao may be deemed to have voting and investment power over the shares of Class A Common Stock held by Boao Biotech Ltd. Mr. Yulin Cao disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (Section 16), except to the extent of his indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

**Signature:** /s/ Yulin Cao as sole Director of Boao Biotech Ltd., for and on behalf of Boao Biotech Ltd.  
**Date:** 2025-06-03-05:00

**Signature:** /s/ Yulin Cao  
**Date:** 2025-06-03-05:00

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**